Biomarker testing is vital for all patients with lung cancer, especially younger individuals who have higher rates of ...

Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase ...

Takeda has shot down candidates acquired in its $525 million Maverick Therapeutics takeover, blowing a hole in its oncology R ...

BioDlink, a leading global CDMO, proudly congratulates its partner Junshi Biosciences (HKEX-1877; SSE-688180), on receiving Investigational New Drug (IND) approval from the National Medical Products ...

In the recent study, Ramalingam found that people with Stage III lung cancer who had EGFR mutations had an 84% lower risk of ...